FTC eyes crackdown on improper drug patents in FDA's Orange Book

After a clutch of lawmakers last month challenged “sham patents” registered with the FDA’s Orange Book—the registry for patents of approved drugs—the Federal Trade Commission (FTC) is getting in on the action.